GPC3: Glypican-3
Cell surface proteoglycan.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on GPC3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Codrituzumab | Phase 2 | Chugai Pharmaceutical | Antibody | InhibitorGlypican-3 inhibitor | 1 |
| Trial | Drug | Phase | Status | Lead sponsor | First posted |
|---|---|---|---|---|---|
| A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment | Codrituzumab | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | Jun 16, 2021 |
- Simpson-Golabi-Behmel syndrome type 10.77
- Simpson-Golabi-Behmel syndrome0.74
- Wilms tumor 10.72
- COVID-190.54
- Hereditary disease0.49
- Dengue disease0.46
- Thyroid gland papillary carcinoma0.39
- Pancreatic ductal adenocarcinoma0.38
- Kidney neoplasm0.37
- Pancreatic neuroendocrine tumor0.37
- Exocrine pancreatic carcinoma0.37
- Polydactyly0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630889, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P51654, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets